Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2007-07-13
2011-11-15
Badio, Barbara P (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C514S410000, C552S595000, C540S469000, C530S387100, C424S001690
Reexamination Certificate
active
08058266
ABSTRACT:
The present invention describes linking a therapeutic agent to a compound which is known to be naturally concentrated in a tissue affected by, or that is causing, a disease, to create a prodrug for treatment of the disease. Embodiments of the present invention include a new class of carotenoid-linked drugs to treat such blinding retinal disease such as age-related macular degeneration, retinoblastoma, and diabetic macular edema. For example, the present invention comprises a method for the treatment of a disorder of the eye comprising linking a therapeutic agent to a xanthophyll carotenoid to create a prodrug, and administering a therapeutically effective amount of the prodrug to an individual in need of treatment. Provided are prodrugs for treatment of retinoblastoma, cystoid macular edema (CME), exudative age-related macular degeneration (AMD), diabetic retinopathy, diabetic macular edema, or inflammatory disorders.
REFERENCES:
patent: 5536504 (1996-07-01), Eugster et al.
patent: 6001885 (1999-12-01), Vega et al.
patent: 7259180 (2007-08-01), Marcus et al.
patent: WO 91/05806 (1991-05-01), None
patent: WO 00/56367 (2000-09-01), None
Garnett, M., “Targeted Drug Conjugates: Principles and Progress,” Advanced Drug Delivery Reviews, vol. 53, No. 2, 171-216, 2001.
Han, H.K. et al., “Targeted Prodrug Design to Optimiize Drug Delivery,” AAPS Pharmsci 2000, vol. 2, No. 1, Article 6, 1-11, 2000 (http://www.pharmsci.org/).
Moeller, S. et al., “The Potential Role of Dietary Xanthophylls in Cataract and Age-Related Macular Degeneration,” Journal of the American College of Nutrition, vol. 19, No. 5, 522S-527S, 2000.
Ramakrishnan, S. et al., “Targeting Tumor Vasculature Using VEGF-Toxin Conjugates,” Methods in Molecular Biology, vol. 166, 219-234, 2001.
Supplementary Partial European Search Report mailed Feb. 28, 2008 corresponding to PCT/US0325229.
Aiello et al., “Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders,”N. Engl. J. Med., 1994, 331: 1480-1487.
Aiello et al., “Hypoxic regulation of vascular endothelial growth factor in retinal cells,”Arch. Ophthalmol., 1995, 113:1538-1544.
Beatty et al., “Macular pigment and risk for age-related macular degeneration in Subjects from a Northern European population,”Invest Ophthalmol. Vis. Sci., 2001, 42: 439-446.
Beatty et al., The role of oxidative stress in the pathogenesis of age-related macular degeneration,Surv. Opthalmol., 2000, 45: 115-134.
Berendschot et al., “Influence of lutein supplementation on macular pigment, assessed with two objective techniques,”Invest. Ophthalmol. Vis. Sci., 2000, 41: 3322-3326.
Bernstein et al., “Retinal tubulin binds macular carotenoids,”Invest. Ophthalmol. Vis. Sci., 1997, 38: 167-175.
Blair et al., “Cystoid macular edema after ocular surgery,” In Albert DM, Jakobiec FA, eds.Principles and Practice of Ophthalmology: Philadelphia: WB Saunders, 2000, 2080-2088.
Bone et al., “Preliminary identification of the human macular pigment,”Vision Res., 1985, 25: 1531-1535.
Bone et al., “Stereochemistry of the human macular carotenoids,”Invest. Ophthalmol. Vis. Sci., 1993, 34: 2033-2040.
Bone et al., “Distribution of lutein and zeaxanthin stereoisomers in the human retina,”Acad. Press., 1997, 44: 211-218.
Bone et al., “Lutein and zeaxanthin in the eyes, serum and diet of human subjects,”Experimental Eye Research, 2000, 71: 239-245.
Cooperwood et al., “Nucleoside and nucleotide prodrugs,” In:Recent Advances in Nucleosides: Chemistry and Chemotheraphy, CK Chu, ed. 2002, 91-147.
Doft, “The endophthalmitis vitrectomy study,”Arch. Ophthalmol., 1991, 109: 487-488.
Flach et al., “Improvement in visual acuity in chronic aphakic and pseudophakic cystoid macular edema after treatment with topical 0.5% ketorolac tromethamine,”Am. J. Opthalmol., 1991, 112: 514-519.
Flach et al., “Effectiveness of ketorolac tromethamine 0.5% ophthalmic solution for chronic aphakic and pseudophakic cystoid macular edema,”Am. J. Ophthalmol., 1987, 103: 479-486.
Fung, “Vitrectomy for chronic aphakic cystoid macular adema. Results of a national collaborative, prospective, randomized investigation,”Ophthalmology, 1985, 92: 1102-1111.
Goodwin, “Metabolism, nutrition, and function of carotenoids,”Ann. Rev. Nutr., 1986, 6: 273-297.
Guex-Crosier, “The pathogenesis and clinical presentation of macular edema in inflammatory diseases,”Doc. Ophthalmol., 1999, 97: 93-105. (93-105).
Hammond et al., “Iris color and macular pigment optical density,”Exp. Eye Res., 1996, 62: 293-297.
Hammond et al., “Dietary modification of human macular pigment density,”Invest. Ophthalmol. Vis. Sci., 1997, 38: 1795-1801.
Jampol et al., “Antioxidants and zinc to prevent progression of age-related macular degeneration,”JAMA, 2001, 286(19): 2466-2468.
Johnson et al., “Relation among serum and tissue concentrations of lutein and zeaxanthin and macular pigment density,”Am. J. Clin. Nutr., 2000, 71: 1555-1562.
Kaplan et al., “Carotenoid composition, concentrations, and relationships in various human organs,”Chin. Physiol. Biochem., 1990, 8: 1-10.
Kliffen et al., Increased expression of angiogenic growth factors in age-related maculopathy,Br. J. Ophthalmol., 1997, 81: 154-162.
Landrum et al, “A one year study of the macular pigment: The effect of 140 days of a lutein supplement,”Exp. Eye Res., 1997, 65: 57-62.
Landrum et al., “The macular pigment: a possible role in protection from age-related macular degeneration,”Adv. Pharmacol., 1997, 38: 537-556.
Leung et al., “Absorption and tissue distribution of zeaxanthin and lutein in rhesus monkeys after taking fructus lycii (Gou Qi Zi) Extract,”Invest. Ophthalmol. Vis. Sci., 2001, 42: 466-471.
Lumbroso et al., “Chemothermotherapy in the management of retinoblastoma,”Ophthalmology, 2002, 109: 1130-1136.
Marcus, D. et al., “Carotenoid-Mediated Delivery of Ketorolac and Triamcinolone,” Invest. Ophthalmol. Vis. Sci., 47: Abstract #3803, 2006. Also presented at Annual Meeting of Association for Research in Opthalmology, Ft. Lauderdale, Florida, May 2006, Retina Society Meeting, San Diego, CA, Sep. 2005, and Macula Society Meeting, San Diego, CA, Feb. 2006.
Marcus, D. et al., “Carotenoid-Mediated Delivery of Ketorolac and Triamcinolone,” Department of Ophthalmology, University of South Carolina, Columbia, SC. Poster Presented at Annual Meeting of Association for Research in Ophthalmology, Ft. Lauderdale, Florida May 2006, and Retina Society Meeting, San Diego, CA Sep. 2005.
Mares-Perlman et al., “Lutein and zeaxanthin in the diet and serum and their relation to age-related maculopathy in the third national health and nutrition examination survey,”Am. J. Epidemiol., 2001, 153: 424-432.
Pendergast et al., “Vitrectomy for chronic pseudophakic cystoid macular edema,”Am. J. Ophthalmol., 1999, 128: 317-323.
Pratt, “Dietary prevention of age-related macular degeneration,”J. Am. Optom. Assoc., 1999, 70: 39-47.
Schalch, “Carotenoids in the retina—a review of their possible role in preventing or limiting damage caused by light and oxygen,”Free Radicals and Aging, 1992, 280-298.
Seddon et al., “Dietary carotenoids, vitamins A, C, and E and advanced age-related macular degeneration,”JAMA, 1994, 272: 1413-1420.
Sec et al., “Dramatic inhibition of retinal and choroidal neovascularization by oral administration of a kinase inhibitor,”Amer. J. Pathology, 1999, 154: 1743-1753.
Shin et al., “Role of protein kinase C isoforms in phorbol ester-induced vascular endothelial growth factor expression in human glioblastoma cells,”J. Biol. Chem., 1999, 274(22): 15407-15
Chu Chung Kwang
Marcus Dennis Michael
Badio Barbara P
Coleman Henry D.
Sapone William J.
Sudol R. Neil
The University of Georgia Research Foundation, Inc
LandOfFree
Methods and compositions for treatment of macular and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for treatment of macular and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for treatment of macular and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4260330